OTLK Outlook Therapeutics, Inc. Common Stock

XNAS 0.59 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

OTLK $0.59 —
Key stats
$0.59
52-Week Range
$0.16 – $2.54
YTD
-11.29%
IV Rank (30D)
90.1
Straddle Price
$0.47
P/C Vol Ratio
0.74
Market Cap
$0.1B
Open
$0.56
Day Range
$0.56 – $0.59
Volume
419,507
Prev Close
$0.56
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)5.15%
Beta vs SPY0.98
Cost of Equity (CAPM)10.03% (VRP-adj)
WACC8.66%
Volatility Risk Premium+307.1pp (IV − HV30)
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)-10.0%
DCF Horizon5 years explicit + fade
Free Cash Flow (TTM)$-0.1B
Return on Equity (TTM)460.2%
Book / Price-96.6%
Gross Margin (TTM)-45.6%
FCF Margin (TTM)-13215.2%
Quality Score1/6 — cyclical/struggling (5y DCF)
SMA 50$0.64 (Market Anchor value)
SMA 20 / Bollinger Mid$0.57
Bollinger Width / SMA206214.9% (drives anchor stability)
Net Debt$0.0B
Market Cap$0B
60-Day Conviction
87%
20-Day Fair Value
≈ by Nov 20, 2026
$0.57
α -0.3% rank 71%
conviction
20%
40-Day Fair Value
≈ by Dec 21, 2026
$0.58
α +1.6% rank 75%
conviction
50%
60-Day Fair Value
≈ by Jan 19, 2027
$0.60
α +3.4% rank 76%
conviction
87%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0%
Peer EV/EBITDA n/a 0%
Peer P/B n/a 0%
Peer P/S n/a 0%
Market Anchor (SMA50) $0.64 100% stability 65% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-10-22 · updated
About
Industry (SIC)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
Exchange
XNAS
Market Cap
$0.1B
Employees
17
List Date
2016-05-13
CIK
0001649989
Headquarters
Iselin, NJ
Homepage
https://www.outlooktherapeutics.com

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First …

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan-22.72%-2.74%9.52%-1.81%0.00%-33.38%-8.52%
Feb92.04%9.40%-6.84%20.50%-18.92%-4.39%15.30%
Mar4.65%5.95%0.93%46.94%-14.08%-51.23%-1.14%
Apr7.69%-16.22%-1.87%-13.06%28.69%19.05%4.05%
May13.56%-27.22%28.21%-16.82%17.20%178.41%32.22%
Jun-9.78%-4.67%6.75%5.43%-9.60%88.61%12.79%
Jul-9.60%10.78%1.17%4.59%24.05%-34.89%-0.65%
Aug22.12%-0.88%-86.35%-0.68%-55.90%-30.62%-25.39%
Sep-18.42%10.91%-2.26%-20.77%21.83%-7.96%-2.78%
Oct-3.72%-6.45%168.22%10.34%21.15%1.27%*31.80%
Nov-27.40%-9.57%-24.10%-66.12%37.69%---17.90%
Dec5.43%2.86%-16.67%-6.90%-15.05%---6.07%
Total13.73%-30.56%-68.33%-62.03%-10.29%-18.23%-29.29%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $0.57
SMA 50: $0.63
SMA 200: $0.66
Current: $0.58
EMA 12: $0.55
EMA 26: $0.59
MACD: -0.0386 | Signal: 0.0075
BEARISH
ADX (14): 22.67
WEAK TREND
+DI: 21.65
−DI: 24.73

Momentum Oscillators

RSI (14): 48.76
NEUTRAL
Stoch %K: 64.05
Stoch %D: 47.94
Williams %R: -20.70

Volume & Volatility

BB Upper: $0.66
BB Lower: $0.47
NEUTRAL
OBV: 53,725,786
Vol SMA 20: 4,404,383
Vol ROC: -89.52%
ATR: $0.05
True Range: $0.03
HV 20: 94.2%
HV 30: 82.6%
HV 60: 95.8%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-21T00:00:00
AI Analysis

LLM Stock Analysis Report

Executive Summary

Overall assessment: NEUTRAL (Confidence level: 6/10)

Key drivers:

  • Recent FDA approval of LYTENAVA for Wet AMD treatment, which has positively impacted the stock price
  • High volatility in recent trading sessions, indicating market uncertainty and potential catalysts

Primary risks:

  • Market volatility and potential selloffs affecting the overall market sentiment
  • Regulatory changes or delays that could impact the company's product pipeline

Investment thesis: OTLK presents an attractive risk-reward profile as a result of its FDA-approved treatment for Wet AMD. However, high volatility in recent trading sessions suggests market uncertainty, which may impact the stock price.

Recent news sentiment impact: Positive news headlines have had a significant impact on the stock price, driving it higher. The recent FDA approval has boosted investor confidence, while neutral and negative news articles have not had a substantial impact.

Technical Analysis

Trend Direction:

  • Short-term (1-4 weeks): Bullish
  • Medium-term (1-3 months): Neutral
  • Long-term (3-12 months): Bullish

Support/Resistance Levels:

  • SMA 20: $0.69
  • SMA 50: $1.06
  • Upper Bollinger Band: $0.91

Momentum Signals:

  • RSI interpretation: Neutral (36.58)
  • MACD signal: Bearish (Histogram: -0.13)
  • Bollinger Bands position: Squeeze

Volume Analysis:

  • Volume SMA 20: 22282115.70
  • On-Balance Volume (OBV): 45739823.79
  • Volume Rate of Change: -83.26% (indicating lower volume)

News & Sentiment Analysis

Recent Headlines Summary: Positive news headlines have driven the stock price higher, with FDA approval being a significant catalyst.

Sentiment Assessment: Aggregate news sentiment is positive, with 3 out of 6 recent news articles having a positive tone.

Catalyst Identification: Upcoming events:

  • No earnings data available
  • Options activity suggests market expectation for $1.07 move by expiration

Market Narrative: News headlines have aligned with the technical signals, driving the stock price higher. Market uncertainty and high volatility remain concerns.

Risk & Volatility Assessment

Beta Interpretation: Risk relative to market (beta) is 1.01, indicating above-average volatility.

Volatility Regime: Current volatility regime is high, with historical volatility levels indicating potential for further price swings.

Options Market Signals: IV rank is 21.1%, suggesting low volatility and option prices relatively cheap.

Downside Protection: Support levels:

  • SMA 20: $0.69
  • Lower Bollinger Band: $0.46

Market Context & Positioning

Sector Performance: OTLK has outperformed its sector in recent trading sessions, suggesting a strong performance relative to peers.

Institutional Activity: Volume patterns suggest institutional interest and potential accumulation.

Correlation Analysis: The stock is positively correlated with the overall market (R-squared interpretation).

Relative Valuation: Position within trading range:

  • Current price: $0.64
  • SMA 50: $1.06
  • Upper Bollinger Band: $0.91

Key Levels & Action Items

Critical Price Levels:

  • Support: SMA 20 ($0.69), Lower Bollinger Band ($0.46)
  • Resistance: Upper Bollinger Band ($0.91)

Breakout/Breakdown Levels: No clear breakout or breakdown levels identified.

Time-Sensitive Catalysts: Upcoming events:

  • No earnings data available
  • Options activity suggests market expectation for $1.07 move by expiration

Risk Management: Stop-loss levels and position sizing considerations:

  • Use SMA 20 as a support level to set stop-losses
  • Consider reducing positions if price breaks below SMA 20
Generated
News
All OTLK news →
Earnings History
9 of 9 under expected move
Avg Expected Move
91.23%
Avg Actual Move
8.64%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2024-08-14 After-Close 32.02% 4.63% 0.14x Within
2024-12-27 Pre-Market 102.94% 18.24% 0.18x Within
2025-02-14 After-Close 29.41% 8.56% 0.29x Within
2025-05-15 After-Close 61.19% 4.48% 0.07x Within
2025-08-14 Pre-Market 39.91% 14.08% 0.35x Within
2025-12-19 After-Close 9.95% 8.46% 0.85x Within
2026-02-17 After-Close 189.74% 3.01% 0.02x Within
2026-05-13 Pre-Market 319.59% 5.15% 0.02x Within
2026-08-14 After-Close 36.36% 11.13% 0.31x Within

Earnings calendar: this week’s reports with expected vs actual moves →

OTLK Options Activity & IV Rank

OTLK IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 579.1%
7-DTE IV: —
Expected Move: $0.47
7-DTE Move: $0.47
Days to Exp: 29 (2026-11-20)

Options Flow

Call Volume: 62
Put Volume: 46
P/C Volume: 0.742
NEUTRAL
Call OI: 7,210
Put OI: 1,584
P/C OI: 0.22
Total OI: 8,794

ATM Options Pricing

ATM Call: $0.10
ATM Put: $0.38
Call %: 17.1%
Put %: 64.0%

Chain Summary

Chain Volume: 765
Chain OI: 58,052
Last Updated: 10/22/2026
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Dealer Positioning
TYPICAL γ

Estimated net dealer gamma is at the 27th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
27%
vs own history
GEX tilt
+0.83
OI-weighted, today
Vanna tilt
+0.85
δ-sensitivity to IV
Charm tilt
-0.65
δ-decay vs time
Vanna tilt +0.85: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.65: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 3 ATM contracts, 13k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
No data
30 DTE / 10d —
— pts EXTREME
ATM 274.3% / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)90.1HighOct 22
Straddle Price (30 DTE)$0.47Oct 22
Beta Analysis

Risk Metrics

Beta: 0.9722
Alpha: 26.72%
Correlation: 0.0814
R-Squared: 0.7%
Stock Volatility: 152.1%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
Moderate volatility - stock generally follows market
Beta & Alpha Over Time
Notable investors who own OTLK
2 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Millennium Management Hedge fund
Izzy Englander
$92K
0.00%
#3626 of 3716new13F
Rockefeller Capital Management Family office
Rockefeller family
$10K
0.00%
#4021 of 4729new13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

OTLK Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 53,448,409 (as of 2026-03-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

72 filers21,806,839 shares$33.94M value40.80% of float
# Filer Shares Value % of Total % of Float Period
1 Vanguard Capital Management LLC 4,376,872 $6.96M 20.51% 8.19% 2026-06-30
2 PERCEPTIVE ADVISORS LLC 3,139,216 $4.99M 14.71% 5.87% 2026-06-30
3 Marshall Wace, LLP Custodian 1,987,578 $3.16M 9.31% 3.72% 2026-06-30
4 BlackRock, Inc. Custodian 1,668,579 $2.65M 7.82% 3.12% 2026-06-30
5 Vanguard Group Inc Custodian 1,465,167 $2.31M 6.82% 2.74% 2025-12-31
6 Jane Street Group, LLC Custodian 1,425,270 $2.27M 6.68% 2.67% 2026-06-30
7 Geode Capital Management, LLC Custodian 1,245,868 $1.98M 5.84% 2.33% 2026-06-30
8 Susquehanna International Group, LLP Custodian 968,190 $1.54M 4.54% 1.81% 2026-06-30
9 HRT FINANCIAL LP 784,904 $1.25M 3.67% 1.47% 2026-06-30
10 Vanguard Fiduciary Trust Co 661,664 $1.05M 3.10% 1.24% 2026-06-30
11 State Street Corp 539,802 $858.28K 2.53% 1.01% 2026-06-30
12 Sanctuary Advisors, LLC 344,529 $547.80K 1.61% 0.64% 2026-06-30
13 Raymond James Financial, Inc. Custodian 332,051 $527.96K 1.56% 0.62% 2026-06-30
14 GROUP ONE TRADING LLC Custodian 246,428 $391.82K 1.15% 0.46% 2026-06-30
15 Northern Trust Corp Custodian 237,561 $377.72K 1.11% 0.44% 2026-06-30
16 GILPIN WEALTH MANAGEMENT, LLC 625,000 $358.44K 1.06% 1.17% 2026-09-30
17 CANTOR FITZGERALD, L. P. 225,000 $357.75K 1.05% 0.42% 2026-06-30
18 Simplex Trading, LLC Custodian 205,013 $325.97K 0.96% 0.38% 2026-06-30
19 LPL Financial LLC Custodian 184,942 $294.06K 0.87% 0.35% 2026-06-30
20 UBS Group AG Custodian 152,215 $242.02K 0.71% 0.28% 2026-06-30
21 Deutsche Bank AG Custodian 130,700 $207.81K 0.61% 0.24% 2026-06-30
22 Wealth Management Partners, LLC 118,170 $187.89K 0.55% 0.22% 2026-06-30
23 Jefferies Financial Group Inc. 62,500 $99.38K 0.29% 0.12% 2026-06-30
24 Millennium Management LLC Custodian 57,839 $91.96K 0.27% 0.11% 2026-06-30
25 Tower Research Capital LLC (TRC) Custodian 57,391 $91.25K 0.27% 0.11% 2026-06-30
7 filers$1.78M notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $862.10K 48.36% 2026-06-30
2 Jane Street Group, LLC Custodian $277.14K 15.55% 2026-06-30
3 Citadel Advisors LLC Custodian $265.69K 14.91% 2026-06-30
4 Simplex Trading, LLC Custodian $206.54K 11.59% 2026-06-30
5 GROUP ONE TRADING LLC Custodian $105.73K 5.93% 2026-06-30
6 GILPIN WEALTH MANAGEMENT, LLC $57.35K 3.22% 2026-09-30
7 Belvedere Trading LLC $7.95K 0.45% 2026-06-30
5 filers$925.54K notional
# Filer Notional Value % of Total Period
1 Citadel Advisors LLC Custodian $360.29K 38.93% 2026-06-30
2 Susquehanna International Group, LLP Custodian $284.93K 30.79% 2026-06-30
3 Simplex Trading, LLC Custodian $164.56K 17.78% 2026-06-30
4 Jane Street Group, LLC Custodian $91.90K 9.93% 2026-06-30
5 GROUP ONE TRADING LLC Custodian $23.85K 2.58% 2026-06-30

OTLK Insider Trading (Form 4)

Latest: 2026-09-02
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-09-02 Kevin Michael Lundquist Chief Financial Officer Grant (A) +500,000 opt — EDGAR
2026-08-14 Lawrence A Kenyon Chief Financial Officer Buy (P) +101,010 — EDGAR
2026-08-14 Robert Charles Jahr Chief Executive Officer Buy (P) +151,515 — EDGAR
2026-08-14 Ghiath M. Sukhtian Director Buy (P) +5,050,504 $0.99 $5.00M EDGAR
2026-07-29 Faisal Ghiath Sukhtian Director Buy (P) +95,398 $1.05 $100.0K EDGAR
2026-07-23 Robert Charles Jahr Chief Executive Officer Grant (A) +100,000 opt — EDGAR
2026-07-23 Lawrence A Kenyon Chief Financial Officer Grant (A) +210,078 opt — EDGAR
2026-06-03 Yezan Munther Haddadin Director Buy (P) +29,000 $0.83 $24.1K EDGAR
2026-06-01 GMS Ventures & Investments Director Buy (P) +17,079,418 $0.59 $10.00M EDGAR
2026-05-27 Randy H Thurman Director Buy (P) +5,000 $0.43 $2.1K EDGAR
2026-05-27 Yezan Munther Haddadin Director Buy (P) +34,000 $0.44 $15.0K EDGAR
2026-05-27 Faisal Ghiath Sukhtian Director Buy (P) +122,174 $0.41 $50.0K EDGAR
2026-05-27 Kurt J Hilzinger Director Buy (P) +400,000 $0.44 $176.5K EDGAR
2025-10-03 Julian S Gangolli Director Grant (A) +286,734 opt — EDGAR
2025-10-03 Andong Huang Director Grant (A) +340,050 opt — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

OTLK Insider Holdings

8 insiders · @ $0.58
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Ghiath M. Sukhtian Director 24,617,320 $14.33M $5.00M 2 2026-08-14
2 GMS Ventures & Investments Director 22,092,068 $12.86M $10.00M 7 2026-06-01
3 Kurt J Hilzinger Director 423,655 $246.7K $803.0K 13 2026-05-27
4 Faisal Ghiath Sukhtian Director 220,972 $128.7K $188.7K 11 2026-07-29
5 Robert Charles Jahr Chief Executive Officer 151,515 $88.2K $0 3 2026-08-14
6 Lawrence A Kenyon Chief Financial Officer 106,956 $62.3K $28.4K 4 2026-08-14
7 Yezan Munther Haddadin Director 66,167 $38.5K $104.3K 11 2026-06-03
8 Randy H Thurman Director 5,593 $3.3K $2.1K 6 2026-05-27
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

OTLK Board & Officers

As of SEC filings through Sep 2, 2026

Directors 10

Officers 2

10% owners 2

Changes in the last 10 years (44)
Sep 1, 2026Kevin Michael Lundquist became Chief Financial Officer
Aug 23, 2026The company announced the departure of Lawrence A Kenyon as Chief Financial Officer in an SEC filing
Jul 23, 2026Robert Charles Jahr first listed as a director in an SEC filing
Mar 6, 2026The company announced the departure of Julia A Haller from the board in an SEC filing
Sep 5, 2025The company announced the departure of Jeff Evanson as Chief Commercial Officer in an SEC filing
Jul 1, 2025Robert Charles Jahr became Chief Executive Officer
Jan 30, 2025The company announced the departure of Lawrence A Kenyon from the board in an SEC filing
Dec 3, 2024The company announced the departure of C Russell Trenary III from the board in an SEC filing
Dec 3, 2024The company announced the departure of C Russell Trenary III as CEO and President in an SEC filing
Mar 22, 2024Lawrence A Kenyon listed as Chief Financial Officer (previously CEO, Pres, CFO, Treas & Secy) in SEC filings
Nov 30, 2023The company announced the departure of Terry Dagnon as Chief Operations Officer in an SEC filing
Apr 19, 2023Terry Dagnon listed as Chief Operations Officer (previously Chief Operating Officer) in SEC filings
Oct 7, 2022Faisal Ghiath Sukhtian no longer listed as a 10% owner in SEC filings
Aug 11, 2022Julia A Haller became a director
Apr 22, 2022Faisal Ghiath Sukhtian first listed as a 10% owner in an SEC filing
Feb 1, 2022GMS Ventures & Investments first listed as a 10% owner in an SEC filing
Jul 6, 2021C Russell Trenary III became a director
Jul 6, 2021C Russell Trenary III became CEO and President
Jun 19, 2020Andong Huang became a director
Jun 2, 2020Syntone Ventures LLC became a 10% owner
Not reported recently (17)
  • Syntone Ventures LLC · Last reported as a 10% owner in an SEC filing dated Apr 17, 2024
  • BioLexis Pte Ltd. · Last reported as a 10% owner in an SEC filing dated Apr 22, 2022
  • Arun Kumar Pillai · Last reported as a director in an SEC filing dated Feb 1, 2022
  • Joe Thomas · Last reported as a director in an SEC filing dated Oct 7, 2019
  • Kenneth Bahrt · Last reported as Chief Medical Officer in an SEC filing dated Feb 19, 2019
  • Pankaj Mohan · Last reported as a director in an SEC filing dated Jan 17, 2019
  • Joerg Windisch · Last reported as a director in an SEC filing dated Nov 13, 2018
  • Stephen J McAndrew · Last reported as SVP Bus. Strat. & Dev. in an SEC filing dated Oct 24, 2018
  • Elizabeth A. Yamashita · Last reported as VP, Regulatory Affairs in an SEC filing dated Dec 26, 2017
  • Claudio Albrecht · Last reported as a director in an SEC filing dated Nov 2, 2017
  • Albert D. Dyrness · Last reported as a director in an SEC filing dated Oct 30, 2017
  • Scott A Canute · Last reported as a director in an SEC filing dated Oct 30, 2017
  • Todd C Brady · Last reported as a director in an SEC filing dated Oct 30, 2017
  • Scott A. Gangloff · Last reported as SVP, Development & Mfrg in an SEC filing dated Dec 22, 2016
  • Kogan Bao · Last reported as VP, Analytical Sciences in an SEC filing dated Dec 22, 2016
  • Hoke Robin Smith · Last reported as a director in an SEC filing dated Nov 30, 2016
  • Donald J. Griffith · Last reported as a director in an SEC filing dated Nov 28, 2016
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
2 ETFs hold OTLK
2 shown · $5.05M total exposure
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $4.0M — 2026-09-30
2 VXF Vanguard Extended Market ETF Vanguard 0.00% $1.1M — 2026-09-30
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-0.98
TTM Revenue
$424.93K
TTM Net Income
$-47.66M
TTM Op. Cash Flow
$-47.05M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q2 '262026-03-31$127.44K$-4.45M$-0.05$-7.83M
Q1 '262025-12-31$-1.21M$-23.06M$-0.38$-14.94M
Q4 '252025-09-30$-91.79K$-13.29M$-0.19$-12.38M
Q3 '252025-06-30$1.51M$-20.15M$-0.55$-11.90M
Q2 '252025-03-31—$-46.36M$-1.50$-16.58M
Q1 '252024-12-31—$17.38M$0.72$-10.97M
Q4 '242024-09-30—$5.69M$0.76$-16.98M
Q3 '242024-06-30—$44.41M$-0.89$-19.51M
Q2 '242024-03-31—$-114.29M$-8.01$-19.27M
Q1 '242023-12-31—$-11.18M$-0.86$-13.03M
Q4 '232023-09-30—$-12.99M$-0.99$-12.74M
Q3 '232023-06-30—$-20.68M$-1.61$-13.22M
Q2 2026 • period ending 2026-03-31 • filed 2026-05-15
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
—
P/S
73.24
EV/EBITDA
—
EV/Sales
81.19
ROE
—
ROA
-217.7%
Div Yield
0.00%
FCF Yield
-151.16%
Debt/Equity
—
Current Ratio
—
Market Cap
$31.12M
as of 2026-10-22
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
31.90M
SI % of Float
38.43%
Days to Cover
7.11
Short Vol Ratio
57.9%
Free Float
83.00M
Float %
99.9%
Short interest 2026-09-30 • Short volume 2026-10-21 • Float 2026-02-17